Literature DB >> 28108311

RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species.

Zijian Zhou1, Bin Lu1, Chen Wang1, Zongqi Wang1, Tianfei Luo2, Meihua Piao3, Fankai Meng4, Guangfan Chi5, Yinan Luo6, Pengfei Ge7.   

Abstract

Shikonin has been reported to induce glioma cell death via necroptosis, a type of programmed necrosis primarily mediated by RIP1 and RIP3. Although RIP1 and RIP3 are found to regulate some features of necrosis such as energy depletion and cellular membrane disruption, it remains unclear whether RIP1 and RIP3 could modulate DNA double strand breaks (DSBs), which is a crucial event leading to chromatinolysis. In this study, we used glioma cell lines and mice model of xenograft glioma to investigate the roles of RIP1 and RIP3 in shikonin-induced DNA DSBs. We found that shikonin induced upregulation of RIP1 and RIP3, necrosome formation and DNA DSBs in vitro and in vivo. In vitro investigation showed that the DNA DSBs and the reduction of cellular viabilities induced by shikonin were both prevented when RIP1 or RIP3 was pharmacologically inhibited by specific inhibitor or genetically knocked down with siRNA. Then, we proved that suppression of intracellular ROS with antioxidant NAC inhibited DNA DSBs caused by either hydrogen peroxide or shikonin, suggesting that ROS played a crucial role in regulation of DNA DSBs of glioma cells induced by shikonin. Further, we found that RIP1 and RIP3 regulated shikonin-induced overproduction of ROS via causing excessive generation of mitochondrial superoxide and depletion of GSH, indicating that ROS was the downstream signal of RIP1 and RIP3. Taken together, we demonstrated that RIP1 and RIP3 contributed to shikonin-induced DNA DSBs in glioma cells via increase of intracellular ROS levels.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DNA double strand breaks; Glioma cell; RIP1 and RIP3; ROS; Shikonin

Mesh:

Substances:

Year:  2017        PMID: 28108311     DOI: 10.1016/j.canlet.2017.01.004

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  Endoplasmic reticulum stress regulates oxygen-glucose deprivation-induced parthanatos in human SH-SY5Y cells via improvement of intracellular ROS.

Authors:  Hai-Feng Wang; Zong-Qi Wang; Ye Ding; Mei-Hua Piao; Chun-Sheng Feng; Guang-Fan Chi; Yi-Nan Luo; Peng-Fei Ge
Journal:  CNS Neurosci Ther       Date:  2017-10-16       Impact factor: 5.243

2.  Diverse actions of sirtuin-1 on ovulatory genes and cell death pathways in human granulosa cells.

Authors:  Jackson Sapuleni; Magdalena Szymanska; Rina Meidan
Journal:  Reprod Biol Endocrinol       Date:  2022-07-15       Impact factor: 4.982

Review 3.  RIPK3 signaling and its role in the pathogenesis of cancers.

Authors:  Shanhui Liu; Kanak Joshi; Mitchell F Denning; Jiwang Zhang
Journal:  Cell Mol Life Sci       Date:  2021-10-15       Impact factor: 9.207

Review 4.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

5.  Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment.

Authors:  Qiang Wang; Jing Wang; Jiayou Wang; Xiaoli Ju; Heng Zhang
Journal:  Toxicol Res (Camb)       Date:  2021-11-26       Impact factor: 3.524

6.  Flow cytometric detection of hyper-polarized mitochondria in regulated and accidental cell death processes.

Authors:  G Warnes
Journal:  Apoptosis       Date:  2020-08       Impact factor: 4.677

Review 7.  Necroptosis in Immuno-Oncology and Cancer Immunotherapy.

Authors:  Jenny Sprooten; Pieter De Wijngaert; Isaure Vanmeerbeerk; Shaun Martin; Peter Vangheluwe; Susan Schlenner; Dmitri V Krysko; Jan B Parys; Geert Bultynck; Peter Vandenabeele; Abhishek D Garg
Journal:  Cells       Date:  2020-08-01       Impact factor: 6.600

8.  Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.

Authors:  Yang-Ling Li; Xiu Hu; Qing-Yu Li; Fei Wang; Bo Zhang; Ke Ding; Bi-Qin Tan; Neng-Ming Lin; Chong Zhang
Journal:  Mol Med Rep       Date:  2018-08-03       Impact factor: 2.952

9.  Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2.

Authors:  Tong Liu; Sainan Li; Liwei Wu; Qiang Yu; Jingjing Li; Jiao Feng; Jie Zhang; Jiaojiao Chen; Yuting Zhou; Jie Ji; Kan Chen; Yuqing Mao; Fan Wang; Weiqi Dai; Xiaoming Fan; Jianye Wu; Chuanyong Guo
Journal:  J Hepatocell Carcinoma       Date:  2020-02-18

Review 10.  The Therapeutic Effect of Artemisinin and Its Derivatives in Kidney Disease.

Authors:  Ming Xia; Di Liu; Yu Liu; Hong Liu
Journal:  Front Pharmacol       Date:  2020-03-31       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.